Medtronic launched Defeat-HF clinical trials evaluating the feasibility of spinal cord stimulation to improve clinical signs and symptoms of heart failure, according to a company news release.
The Defeat-HF study will examine whether spinal cord stimulation can restore the balance between the sympathetic and parasympathetic nervous systems to improve blood flow, reduce inflammation and restore the heart's function. A neurostimulator connected to the spinal cord will deliver low-intensity pulses. This procedure also requires implanting a neurostimulator in the abdomen.
All patients in the trial are systolic heart failure patients in 15 centers worldwide. They will be implanted with Medtronic PrimeADVANCED neurostimulator and followed for 12 months. During the trial, the device delivers stimulation for 12 hours a day.
Read the news release on the Medtronic Defeat-HF.
Read other coverage on neurostimulators:
- Electronic Spinal Devices to Treat Back Pain Now Used on a Wider Array of Patients
- The Medtronic RestoreSensor Neurostimulator Implants Uses Motion-Sensing Technology to Reduce Pain
The Defeat-HF study will examine whether spinal cord stimulation can restore the balance between the sympathetic and parasympathetic nervous systems to improve blood flow, reduce inflammation and restore the heart's function. A neurostimulator connected to the spinal cord will deliver low-intensity pulses. This procedure also requires implanting a neurostimulator in the abdomen.
All patients in the trial are systolic heart failure patients in 15 centers worldwide. They will be implanted with Medtronic PrimeADVANCED neurostimulator and followed for 12 months. During the trial, the device delivers stimulation for 12 hours a day.
Read the news release on the Medtronic Defeat-HF.
Read other coverage on neurostimulators:
- Electronic Spinal Devices to Treat Back Pain Now Used on a Wider Array of Patients
- The Medtronic RestoreSensor Neurostimulator Implants Uses Motion-Sensing Technology to Reduce Pain